Revolutionizing the Approach to Tardive Dyskinesia

At a recent Southern California Psychiatry Conference, renowned psychiatrist Dr. Jonathan Meyer shed light on the complexities of treating tardive dyskinesia (TD). He boldly stated that the only truly effective treatments are the VMAT 2 inhibitors, highlighting a shift away from traditional D2 blockade medications that have long been the go-to for movement disorders.

The Pitfalls of Conventional Medications

Dr. Meyer cautioned healthcare providers against relying on conventional medications for TD, as they often exacerbate symptoms rather than alleviate them. He emphasized the importance of transitioning patients from anticholinergics to the more promising VMAT 2 inhibitors, urging a careful tapering approach to minimize adverse effects.

Tailored Treatment Plans for Optimal Results

In his engaging presentation, Dr. Meyer outlined the distinct approaches to utilizing two key VMAT 2 inhibitors: deutetrabenazine and valbenazine. Deutetrabenazine is characterized by a stricter titration schedule and requires starting at lower doses, while valbenazine offers greater ease of initiation at lower dosages without compromising effectiveness.

Empowering Clinicians and Patients

The crux of Dr. Meyer’s message was clear: understanding how to employ both treatment options is crucial for clinicians. Factors such as insurance can heavily influence access to medications, making it essential for healthcare providers to be well-versed in these choices. Patients may respond differently to each medication, highlighting the need for personalized care.

Navigating Limited Options for Patients

Despite the potential of VMAT 2 inhibitors, Dr. Meyer acknowledged a challenging reality: only two FDA-approved medications exist for TD treatment. Some patients may not find sufficient improvement with either option, underscoring the importance of seeking referrals to neurologists for further assessment and innovative treatments.

A Call to Action for the Medical Community

Dr. Jonathan Meyer, a voluntary clinical professor of psychiatry at the University of California, San Diego, continues to advocate for enhanced awareness and understanding of tardive dyskinesia management. His insights reflect a pressing need for ongoing education in the mental health community to ensure that patients receive the most effective care.